Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-8.56%
3 Months
-10.10%
6 Months
-51.19%
1 Year
-
3 Years
-79.40%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BFRA---
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.30
0.11
1.55
-3.50
Leverage Ratio 3.50
ProfitabilityValueIndustryS&P 500US Markets
86.90
-43.60
-43.60
-64.80
-79.42
RevenueValueIndustryS&P 500US Markets
21.38M
0.75
-0.02
31.81
Earnings HistoryEstimateReportedSurprise %
Q03 2021--0.24-
Q02 2021--0.17-
Q01 2021--0.22-
Q03 2020--0.28-
Q02 2020-0.04-
Q01 2020--0.31-
Q04 2019--0.22-
Q03 2019--0.59-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume0
Shares Outstanding0
Shares Float0
Trades Count0
Dollar Volume0
Avg. Volume0
Avg. Weekly Volume0
Avg. Monthly Volume0
Avg. Quarterly Volume0

Biofrontera AG (NASDAQ: BFRA) stock closed at 2.67 per share at the end of the most recent trading day (a -9.49% change compared to the prior day closing price) with a volume of 4.90K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 155 people. Biofrontera AG CEO is Hermann Lubbert.

The one-year performance of Biofrontera AG stock is %, while year-to-date (YTD) performance is -10.1%. BFRA stock has a five-year performance of %. Its 52-week range is between and , which gives BFRA stock a 52-week price range ratio of %

Biofrontera AG currently has a PE ratio of -4.60, a price-to-book (PB) ratio of 4.62, a price-to-sale (PS) ratio of 3.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.34%, a ROC of -31.14% and a ROE of -196.77%. The company’s profit margin is -79.42%, its EBITDA margin is -43.60%, and its revenue ttm is $21.38 Million , which makes it $0.75 revenue per share.

Of the last four earnings reports from Biofrontera AG, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biofrontera AG’s next earnings report date is -.

The consensus rating of Wall Street analysts for Biofrontera AG is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Biofrontera AG stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biofrontera AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biofrontera AG has a Sell technical analysis rating based on Technical Indicators (ADX : 22.88, ATR14 : 0.47, CCI20 : -35.09, Chaikin Money Flow : -0.69, MACD : -0.06, Money Flow Index : 0.00, ROC : 0.00, RSI : 42.74, STOCH (14,3) : 14.00, STOCH RSI : 0.00, UO : 15.43, Williams %R : -86.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biofrontera AG in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
-
0.00
-
0.00

Biofrontera AG

Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

CEO: Hermann Lubbert

Telephone: +49 2148733200

Address: Hemmelrather Weg 201, Leverkusen D-51377, , DE

Number of employees: 155

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

68%32%

Bearish Bullish

61%39%

News

Stocktwits